Testing for t(3;8) in MYC/BCL6-rearranged large B-cell lymphoma identifies a high-risk subgroup with inferior survival.

Bernard Douglas MayburyLisa JamesNeil PhillipsIndrani VenkatadasariIman QureshiJames RileyGeorgina TalbotShivir MoosaiHannah GilesNicola ChaddertonJames DowdsPallav RakeshHenry CroslandAidan HaslamSarah LaneMonica Vega GonzalezDavid DaviesGeorge CherianAmir ShenoudaPraveen KaudlayJane StarczynskiZbigniew RudzkiSridhar Chaganti

Published in: Blood (2024)

A reciprocal t(3;8) BCL6::MYC fusion is common in large B-cell lymphoma (LBCL) with MYC and BCL6 disruption. These pseudo-double-hit cases are not adverse, whereas t(3;8)-MYC/BCL6 lymphoma has an inferior prognosis relative to other MYC-rearranged LBCL.

Keyphrases

transcription factor
diffuse large b cell lymphoma
randomized controlled trial
clinical trial
gene expression
dna methylation
free survival
adverse drug
study protocol